Monocytes and monocytoid cell lines previously have been shown t o express receptors for plasminogen and urokinase (u-PA). In the present study, the monocytoid cell lines, U937 and THP-1, are shown t o bind tissue plasminogen activator (t-PA) in a specific, saturable, and reversible manner. These cells bound t-PA with low affinity (kd = 0.67 t o 0.97 pmol/L) and high capacity (0.71 t o 3.3 x 10' receptors/cell). Human peripheral blood monocytes bound t-PA with a kd (0.9 Fmol/L) similar t o that of the monocytoid cells but with a lower capacity (0.17 x lO'sites/cell). These binding parameters also were similar to the low-affinity interaction of t-PA with endothelial cells as measured with the cells in suspension (kd = 0.73 pmol/L and 1.1 x 10' sites/cell). Lysine analogues and active or diisopropylfluorophosphate-inacti- 0006-4971 I91 17809-0022$3.00/0 recognition specificity mediates t-PA binding t o all of these cell types. The existence of a high-affinity binding site for t-PA on monocytoid cells was also explored in detail. Unlike endothelial cells where plasminogen activator inhibitor-1 has been implicated in mediating a high-affinity interaction of t-PA with the cells, no evidence for a role of this inhibitor in ligand binding t o the monocytoid cells was found. Furthermore, using both high and low '%-PA concentrations, competition analyses with lysine analogues or u-PA, or treatment of the cells with carboxypeptidase B, failed t o indicate the presence of distinguishable classes of t-PA binding sites. In sum, low-affinity receptors for t-PA are expressed at high density on monocytes and monocytoid cells, identifying a new element in the fibrinolytic arsenal of these cells.
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0006-4971 I91 17809-0022$3.00/0 recognition specificity mediates t-PA binding t o all of these cell types. The existence of a high-affinity binding site for t-PA on monocytoid cells was also explored in detail. Unlike endothelial cells where plasminogen activator inhibitor-1 has been implicated in mediating a high-affinity interaction of t-PA with the cells, no evidence for a role of this inhibitor in ligand binding t o the monocytoid cells was found. Furthermore, using both high and low '%-PA concentrations, competition analyses with lysine analogues or u-PA, or treatment of the cells with carboxypeptidase B, failed t o indicate the presence of distinguishable classes of t-PA binding sites. In sum, low-affinity receptors for t-PA are expressed at high density on monocytes and monocytoid cells, identifying a new element in the fibrinolytic arsenal of these cells. ell)'^-'^ and a high-affinity site (kd 0.021 to 5.0 nmol/L) of variable capacity (3.7 x lo3 to 1.0 x lO'sites/~eIl).~'~'~'~ The latter interaction may depend on the binding of t-PA to plasminogen activator inhibitor type 1 (PAI-l).'2*'4-'6 Highaffinity interactions of t-PA with hepatocytes, probably dependent on PAI-l,'73'8 and neuronal cell^'^*^^ also have been reported, whereas lower affinity interactions of t-PA with platelets" and fibroblasts" have been shown.
The participation of monocytes in multiple physiologic and pathophysiologic processes, such as the immune response, inflammation, and atherosclerosis, depends on their capacity to localize and regulate the proteases of the fibrinolytic Monocytes constitutively express PAI-1 and PAI-2''*" and, in responses to certain cytokines or endotoxin, these cells can be stimulated to synthesize and secrete t-PA.283 '9 The possibility that monocytes can specifically bind t-PA has been explored in this study. A high-capacity interaction of t-PA with monocytes and monocytoid cells is shown, establishing a new dimension in considering the regulation of the fibrinolytic system by these cells.
MATERIALS AND METHODS

Proteins.
Human recombinant single chain t-PA (rt-PA, Activase) was obtained from Genentech, Inc (South San Francisco, CA). Transferrin, myoglobin, human IgG, and antitrypsin were from Sigma Chemical Co (St Louis, MO), and wantiplasmin was from American Diagnostica Inc (New York, NY). Plasminogen and fibronectin were purified as de~cribed.~"~" High (HMW-u-PA) and low molecular weight (LMW-u-PA) two-chain u-PA were purchased from Calbiochem (La Jolla, CA). For some experiments, u-PA was further purified by affinity chromatography on benzamidine-Sepharose followed by gel filtration on Sephadex G-75 (Pharmacia Fine Chemicals, Piscataway, NJ)?* PAI-3, protein C, factor XII, and prothrombin was generously provided by Dr J.H. Griffin (Research Institute of Scripps Clinic, La Jolla, CA).
To select a method for radiolabeling rt-PA, the products obtained by a modified chloramine-T method," Iodo-Gen,"4 Iodo-Bead~,'~ and immobilized lact~peroxidase~~ were compared. When 2 mCi of '*'I was added in the various procedures, Protein iodination. 2318 Blood, Vol78, No 9 (November 1). 1991: pp 2318-2327
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products of similar specific activities (-4 pCi/pg) were obtained. Fibrin binding activity, measured by the method of Nelles et a! ; ' was used as a criterion to select among these ligands. Compared with nonlabeled t-PA, the fibrin-binding activities of the 9-t-PA preparations radiolabeled by the different methods were as follows: 100% for lactoperoxidase, 86% for Iodo-Gen, 69% for modified chloramine-T, and 46% for Iodo-Beads. Thus, the lactoperoxidase method was used as the radiolabeling procedure in subsequent experiments. In a typical labeling procedure, 50 pL of rt-PA (1 to 5 mg/mL) was mixed with 100 pL of 0.01 mol/L phosphate buffer, pH 7.35 containing 0.1 mol/L arginine (Calbiochem), 50 pL of immobilized lactoperoxidase Enzymobead (BioRad, Richmond, CA), 2 to 8 mCi of Na'=I, and 50 pL of 2% dextrose (Sigma). After a 15-minute incubation at 22"C, the reaction was stopped by adding 10 pL of 1% sodium azide. Free NalZ5I was removed by extensive dialysis in phosphate-arginine buffer. Specific activities of 2 to 8 pCi/pg of protein were attained. Proteolytic activity of '%-t-PA was localized by fibrin gel zymography's at the 65-Kd region. Immediately after labeling, portions of the radiolabeled rt-PA preparations were inactivated by treatment with 5 mmol/L diisopropylfluorophosphate (DFP) for 30 minutes at 4°C. After inactivation, less that 6% of the proteolytic activity was retained based on its capacity to convert plasminogen to plasmin, as detected with the S2251 chromogenic substrate (Kabi, Stockholm, Sweden).
The human monocytoid THP-1 cell line was cultured in RPMI-1640 (Whittaker/M.A. Bioproducts, Walkerville, MD) containing penicillin G (100 U/mL), streptomycin (100 pg/mL), 1 mmol/L Na pyruvate, 0.05 mol/L HEPES pH 7.35, 5 x lo-'% 2-mercaptoethanol, and 5% fetal calf serum (FCS) (Irvine Scientific, Irvine, CA). The human monocytoid U937 cell line was grown in RPMI-1640 containing penicillin G (100 U/mL), streptomycin (100 pg/mL), and 5% FCS.
Monocytes, neutrophils, and red blood cells (RBCs) were isolated from blood collected into heparin 5 U/mL (Sigma), theophylline (10 mmol/L), and prostaglandin E,, (10 pg/mL). Immediately after collection, the blood was centrifuged at 500g for 10 minutes, and the platelet-rich plasma (PRP) was removed. Monocytes were isolated from the packed cells using Sephracell-MN (Sephratec Co, Oklahoma City, OK) as de~cribed?~ The monocytes obtained were suspended in Hanks' balanced salt solution containing 1.2 mmol/L CaCl,, 1.6 mmol/L MgSO,, 0.05 mol/L HEPES, pH 7.35 (HBSS-HEPES) and 2% bovine serum albumin (HBSS-HEPES-BSA), and their purity was assessed by microscopic examination after Giemsa (Harleco, Gibbstown, NJ) and esterase staining. Only monocyte preparations containing less than 20% platelets and less than 10% of lymphocytes were used in this study.
Neutrophils and RBCs were also prepared from packed cells after removal of the PRP as described previously. The cell pellet was reconstituted to the original whole blood volume with RPMI and centrifuged onto Ficoll-Hypaque (8% Ficoll [Sigma] 10%
Hypaque [Winthrop-Breon, New York, NY] density = 1.3570) at 7% for 30 minutes at 22°C. The cell pellet was suspended in phosphate-buffered saline (PBS) and mixed with 2 parts 3% dextran T-500 (Pharmacia, Uppsala, Sweden). The RBCs were allowed to settle and the top layer, containing neutrophils, was removed. Both cell fractions were washed three times in HBSS-HEPES and suspended in HBSS-HEPES-BSA for use as the RBC or neutrophil populations. As determined by Giemsa staining, mononuclear cell contamination of the neutrophils was less than 1%, and the RBCs contained less than 0.5% leukocytes and platelets. Viability of leukocytes was assessed by trypan blue exclusion and recovery by counting of cells using a hemocytometer.
Platelets were isolated from human blood collected into acid/ and 10 mmol/L EDTA and counted. Molecules of '=I-rt-PA bound per cell were calculated based on the specific activity of the ligand. Specific binding was defined as that component of bound radioactivity that could be inhibited by a 50-to 200-fold molar excess of unlabeled t-PA. Dissociation constants (kd) were determined from specific binding isotherms using a nonlinear curve-fitting computer program, Ligand?l Linear correlation coefficients were calculated with a TI-55-11 calculator (Texas Instruments Inc, Dallas, TX). Means f standard deviations were compared for statistical significance using a paired t-test.
Sodium dodeql suvate-polyacrylamidelamide gel electrophoresis (SDS-PAGE). Cell-bound '=I-t-PA was extracted with 0.1% Triton X-100 in 0.1 mol/L TrisHC1, pH 8.1, containing 10 mmol/L EDTA, 1.0 mmol/L phenylmethylsulfonyl fluoride (PMSF), and 100 U/mL trasylol (FBA Pharmaceuticals, New York, NY). Extracts were boiled for 5 minutes before electrophoresis in the presence of 2% 2-mercaptoethanol. PAGE in the presence of SDS was performed on 7.0% to 8.0% gels run under reducing conditions in the buffer system of Laemmli,' or Weber and Osborn.4? Gels were stained with Coomassie Blue, dried, and autoradiograms were developed with XRP-1 film (Eastman Kodak Co). The autoradiograms were scanned using a Zeineh soft laser densitometer (Biomed Instruments Inc, Fullerton, CA). Molecular weights were estimated based on mobility relative to standard proteins obtained from Amersham (Arlington Heights, IL). In experiments to detect t-PA-PAI complexes the extracts were not boiled, were dissolved in 0.1% SDS, and were electrophoresed in the phosphate buffer system of Weber and Osb0rn.4~ timc-dcpcndcnt hinding of thc '."I-rt-PA to THP-I cclls (a monocytoid ccll linc that cxhihits many characteristics of human pcriphcral hltmd monocytcs) was ohscrvcd ( Fig  I) .""' At 4°C. apparcnt stcady-st;rtc binding was achicvcd hy 90 minutcs with cithcr untrcatcd or DFP-trcatcd "'I-rt-PA. and no substantial ditfcrcnccs wcrc notcd in thc hinding of thcsc two ligands to thc cclls. At 00 minutcs, THP-I cclls hound 6.82 5 0.48 x IO' and 6.74 t 0.36 x IO' molcculcs pcr ccll of untrcatcd or DFP-trcatcd '"I-rt-PA, rcspcctivcly. Similar timc-coursc cxpcrimcnts wcrc pcrformcd with a IO-fold lowcr input conccntration of ligand (IS nmol/L). and appircnt cquilibrium was again attaincd at 90 minutcs. With a sccond monocytoid ccll linc. U037, apparcnt cquilihrium of rt-PA also was attaincd hy 90 minutcs and thc cxtcnt of hinding was similar to that ohscrvcd with thc THP-I cclls. At a 250 nmol/L input conccntration. the UY37 cclls hound 5.32 t 1.1 x 10' and 5.84 2 0.7 x IO' molcculcs pcr ccll of "'I-rt-PA and its DFP-inactivatcd dcriviitivc. rcspcctivclv. aftcr a 90-minutc incuhation ilt 4°C. !-PA binding to thc UY37 cells was only modcstly affcctcd hy tcmpcraturc, showing about il 4 0 5 incrcasc at 37°C comparcd with 4°C at a 90-minutc timc p i n t .
C/iaracirnzaiion of thr '-"/-li,cand boitnd io monocytoid celk
The charactcristics of thc ligand hound to monocytoid cclls wcrc asscsscd hy SDS-PACE undcr conditions whcrc single-chain rt-PA could hc distinguished from two-chain rt-PA (Fig 2) . As dctcrmincd hv dcnsitomctric scanning of autoradiograms. 80r'i t S r i of '"I-rt-PA addcd to thc cclls was in thc single-chain form with an apparcnt molecular wcight of 65 Kd (Fig 2. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From plasmin treatment (30-minute incubation at 37°C with a 10-fold molar excess of plasmin), 90% conversion to the two-chain form was observed (Fig 2, lane B) . The cellbound '*'I-rt-PA (Fig 2, lane C) was comprised of a major band at 65 Kd. In addition, the unbound ligand, lane D, was also predominantly in the single-chain form. The amount of two-chain '"I-rt-PA in lanes C and D was similar, approximately 15% total radioactivity in these lanes as determined by densitometric scanning. Thus, the monocytoid cells were capable of binding single-chain rt-PA, alteration of the ligand was not observed; and, on a relative basis, marked preferential recognition of single-versus two-chain rt-PA was not apparent.
Specificity, reversibility, and saturability of t-PA binding. The specificity of binding of rt-PA to monocytoid cells was determined by adding excess unlabeled rt-PA or unrelated proteins to mixtures of '"I-rt-PA and monocytoid cells. The results obtained with U937 cells are summarized in Table 1 , and similar results were obtained with THP-1 cells. With radiolabeled rt-PA added at 25 nmol/L, a 100-fold excess of unlabeled rt-PA inhibited its binding by 70%, which is defined as 100% specific binding in Table 1 After 10 and 30 minutes, the excess unlabeled rt-PA dissociated 45% and 65% of bound material, respectively. At the 30-minute time point, the amount of residual '"I-ligand (35%) was similar to the level of nonspecific binding (30% 2 ll%), suggesting that under the conditions described, rt-PA binding to monocytoid cells was fully reversible.
With evidence for the specificity and reversibility of Time (mid As monocytes can be induced to synthesize and secrete t-PA,ZS2q the possibility of endogenous occupancy of t-PA receptors on the monocytoid cells was assessed. A shortterm acid treatment of cells was used to dissociate bound ligand. When '"I-rt-PA was bound to THP-1 cells for 2 hours, it could be 70% to 74% dissociated by a 10-minute exposure to pH 3.5 at 4°C. After such acid treatment, the cells bound rt-PA with a kd of 1.08 f 0.78 pmol/L and Binding of rt-PA to human monocytes and to otherperiphera1 blood cells. To determine if the binding of rt-PA to monocytoid cells was reflective of the interaction of the ligand with monocytes, human peripheral blood monocytes were isolated by centrifugation of blood through Sephracell-MN, and IxI-rt-PA binding was assessed. Binding isotherms were constructed at P C , and the kd and number of binding sites were derived from Scatchard plots. Isolated peripheral blood monocytes bound rt-PA with a kd of 0.9 ? 0.4 pmol/L and 1.7 +: 1.0 x lo5 molecules were bound per cell (n = 6).
To determine whether the ability to bind rt-PA was unique to monocytes, the interaction of the ligand with other blood cells was analyzed. 1251-rt-PA, at 40 to 60 nmol/L, was added to isolated blood cell populations, and binding was measured after 2 hours at 4°C. No specific binding of the ligand to RBCs or resting platelets was detected (Table 2) ; based on the sensitivity of the assay used, these cell types bound less than 800 molecules of rt-PA per cell. In contrast, specific rt-PA binding to neutrophils was detected. In five experiments in which binding to neutrophils and monocytes was measured in parallel, the extent of ligand binding to the two cell types was very similar (see Table 2 ). Thus, neutrophils, as well as monocytes, have the capacity to specifically bind rt-PA.
Comparison of rt-PA binding to monocytes and endothelial cells. As endothelial cells express a low-affinity, high- capacity binding site for t-PA,'".15 we sought to determine if the interactions of rt-PA with monocytoid and endothelial cells share common characteristics. Endothelial cell binding of t-PA has been reported to be inhibited by L-lysine, 6-AHA, and arginine.l0," As summarized in Table 3 , these compounds also inhibited the binding of DFP-treated I-rt-PA to monocytoid cells. The IC,, (concentration producing 50% inhibition) values obtained for these compounds are very similar with THP-1 and HUVEC in suspension, and these values are also similar to those reported for adherent HUVEC in the literature.103" These compounds also inhibited the binding of active rt-PA to the two cell types. For example, with DFP-treated 1251-rt-PA, the IC, values for 6-AHA were 4 t 1 and 12 r 3.5 mmol/L for THP-1 and HUVEC, respectively, whereas with active '*'I-rt-PA, the IC,, values were 5.2 f 2.1 and 7.2 t 3.2 mmol/L, respectively. u-PA has also been reported to partially inhibit t-PA binding to endothelial cells.11.'2 As indicated in Table 3 , HMW-u-PA effectively inhibited DFP-'%rt-PA binding to THP-1 and the suspended HU-VEC; the IC,, values observed with the two cell types were in the range of 30 to 80 nmol/L for DFP-treated HMW-u-PA. Similar results were obtained when competition assays were performed with active "'I-rt-PA (IC5, = 35 to 60 nmol/L) and with U937 cells. Furthermore, when the HMW-u-PA was subjected to additional purification on benzamide-Sepharose followed by gel filtration, its inhibitory activity was retained. In contrast, LMW-u-PA failed to inhibit '''I-rt-PA binding to THP-1 or HUVEC at concentrations as high as 1 pmol/L. The capacity of HMW-u-PA to inhibit rt-PA binding to cells was not shared by other structurally related proteins. Factor XI1 (two kringle, one finger, and two growth factor domains), prothrombin (two kringles), and protein C (two growth factor domains) failed to inhibit rt-PA (two kringles, one finger domain, one growth factor domain) binding at concentrations of 1 to 2 pmol/L.
To determine whether the recognition specificity of monocytoid and endothelial cells for rt-PA was also shared by monocytes, the capacity of the various competitors to inhibit rt-PA binding to isolated human peripheral blood monocytes was assessed. As the number of monocytes available was limiting, single concentrations of the competitors were tested. As shown in Table 4 , L-lysine, 6-AHA, 125 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From U937 cells were treated with trypsin-EDTA under the same conditions used to suspend the HUVEC. At an input concentration of 0.1 pmol/L "'I-rt-PA, the trypsin-treated cells bound 3.1 2 0.1 x 10' molecules/cell, whereas the untreated cells bound 3.3 & 0.3 x lo5 molecules/cell, indicating that the enzymatic treatment had minimal effects on the capacity to bind the ligand.
Search for a high-afinity interaction of rt-PA with monocytoid cells. In view of the similarities between the lowaffinity binding of rt-PA to monocytoid and to endothelial cells, we sought to determine whether monocytoid cells are also endowed with a high-affinity binding site for the ligand. The high-affinity site (kd = 28 pmol/L to 5.0 nmol/L) for t-PA on endothelial cells appears to be PAI-l'z,'43'6; and PAI-1 has been reported to be present in monocytoid cells.27 As a first step to consider the role of PAI-1 in t-PA binding to the cells, we determined the level of PAI-1 present in THP-1 and U937 cells. Using an immunoassay for PAI-1, less than 2,800 molecules of PAI-1 were present per cell in the two cell types. Thus, the potential contribution of PAI-1 to the total binding capacity of the THP-1 cells could be no greater than 1%. As a separate approach to consider the role of PAI-1 or other PAI-mediated interactions of rt-PA with monocytoid cells, a radiolabeled rt-PA preparation was used that retained full enzymatic as well as fibrin-binding activity. This ligand was added to the monocytoid cells at low (0.1 nmol/L) and high (100 nmol/L) input concentrations to maximize detection of a putative high-as well as low-affinity interactions. After a 2-hour incubation with the cells, the unbound and free ligand were recovered and analyzed by SDS-PAGE. The autoradiograms obtained were similar to those shown in Fig 2. Namely, even at the low input concentration of IzI-rt-PA, no evidence of an SDS-stable complex between the added ligand and an inhibitor in either the cell-bound or unbound material was detected. As a control for this experiment, a preformed '251-rt-PAPAI-1 complex was added to the cells and subjected to extraction and SDS-PAGE; this complex remained intact when subjected to the analysis. Thus, no evidence for formation of stable complexes between rt-PA and cell-associated inhibitors was found.
To maximize the potential to detect a high-affinity t-PA binding site, additional binding isotherms were constructed to include at least seven Y-rt-PA input concentrations below 10 nmol/L. Data from such experiments were subjected to Scatchard analyses using the Ligand Program:' As shown in Fig 5A, the data points yielded a curvilinear Scatchard plot, and the fit of these points to a two-site model was statistically superior to a one-site model. The residual variance (mean square) was 51.31 in a two-site model compared with 205.44 in the one-site model. Variances were statistically compared by the extra sum of squares principlea and the "F" ratio obtained was 17.52 (P = .001). In the two-site model, the apparent kd of the high-affinity site was 60 & 34 pmol/L, with 1.9 2 1.5 x lo4 binding sites per cell (n = 8). Similar results were obtained using DFP-treated radiolabeled ligand: kd = 33 2 16 pmol/L and 1.5 2 1.1 x lo4 binding sites per cell (n = 8).
Great caution must be taken in interpreting nonlinear
For For example, at 10 nmol/L lzI-rt-PA the experimentally determined and the predicted specific binding were 44% and 40% of total binding, respectively. In contrast, at input concentrations of lZI-rt-PA below 1 nmol/L, the experimentally determined specific binding decreased precipitously to 10% to 24% of total binding. Thus, when the same data that gave the curvilinear Scatchard plot in Fig 5A, using the ligand program-derived estimate of nonspecific binding, were recalculated using the experimentally estimated values for nonspecific binding at each data point below 10 nmol/L, the linear plot in Fig 5B was obtained. With these data, a one-site model was appropriate with an apparent kd of 784 2 173 nmol/L (mean ? SD of two separate experiments using two different concentrations of unlabeled rt-PA to determine nonspecific binding). These analyses suggest that nonspecific binding may not be a constant percent of the added ligand concentration, an assumption of the Ligand Program, resulting in curvilinear Scatchard plots.
To further discriminate between one-or two-site models of t-PA binding to monocytoid cells, two sets of additional experiments were performed. First, inhibition by L-lysine, 6-AHA, and arginine, as well as active and DFP-treated HMW-u-PA, of lzI-rt-PA binding to THP-1 cells was assessed at two different input concentrations (100 and 0.1 nmol/L) of active and DFP-treated radiolabeled ligand. We calculated that if the affinity estimated for the high and low sites (see above) were correct, when radiolabeled ligand was added at an input concentration of 0.1 nmol/L, 98% of the ligand bound to the cell would be associated with the high-affinity site, and at 100 nmol/L 82% of the bound ligand would be associated with the low-affinity site. Thus, if the recognition specificities of the two putative sites were different, the potency of the various inhibitors would be different. However, as summarized in Table 5 , the inhibitory activities of these various agents were very similar at the low and high ligand concentrations with both active and inactive t-PA.
In the second set of experiments, the cells were treated with carboxypeptidase B (CPB) to remove carboxy-terminal lysyl residues that might function as t-PA binding sites and then assayed for their capacity to bind radiolabeled DFPrt-PA at 40, 4, and 0.4 nmol/L input concentrations. The results of this analysis are summarized in Table 6 . IzI-rt-PA binding was inhibited by CPB, and the extent of inhibition was dependent on the CPB concentration. At each CPB concentration, the extent of inhibition was similar at the three different input concentrations of radiolabeled rt-PA.
DISCUSSION
U937 and THP-1 human monocytoid cell lines have been widely used as models to study the regulation of the fibrinolytic system of monocytes. These cells can elaborate plasminogen activators and plasminogen activator inhibitors, properties shared with monocytes and/or macrophages. These cells also express plasminogen and u-PA receptor~,5"'~~ providing a mechanism for the regulation of For personal use only. on September 24, 2017. by guest www.bloodjournal.org From plasminogen activation on the cell surface. In this study, we have shown that U937 and THP-1 monocytoid cells also express specific receptors for t-PA. The binding parameters obtained were similar for both cell lines; namely, they bound t-PA with a relatively low affinity but a high capacity. Single-chain rt-PA bound to these cells and conversion to the two-chain form was not necessary for binding. Although not directly investigated, gel analyses of the bound ligand suggested that two-chain rt-PA also bound to the cells. Recognition of both forms of the ligand by endothelial cells was reported by Aerts et aI,l3 although they noted preferential binding of the single-chain form. Freshly isolated human peripheral blood monocytes also bound t-PA. The affinity of monocytes for the ligand was similar to that of the monocytoid cells, but their capacity was considerably (4-to 20-fold) lower. This relationship of a similar affinity but a lower capacity of monocytes compared with the monocytoid cells is also observed for plasminogen receptors and could be related to the state of cell differentiation or to a basic difference between the normal and the transformed phenotype. While not characterized in detail, specific binding of t-PA to neutrophils also was detected. Thus, neutrophils share with monocytes the capacity to interact with the three fibrinolytic ligands, t-PA, u-PA, and pla~minogen.~ In contrast, RBCs bound less than 800 molecules of t-PA per cell, indicating that these cells lack receptors for all three fibrinolytic ligands.' Recently, a low-affinity interaction of t-PA with platelets has been reported.*' Under the conditions used, we found that resting platelets bound less than 500 molecules of t-PA per cell. The basis for this difference is unknown, although others5' have also failed to detect saturable binding of t-PA to platelets. As our t-PA ligand can bind to other cell types but not to platelets, a basic difference in the recognition of t-PA by the various cell types is suggested. The capacity of lysine analogues to inhibit t-PA binding to endothelial cells and monocytes but not to plateletsz1 is consistent with this conclusion. The t-PA binding parameters obtained on monocytes and monocytoid cells were similar to the low-affinity interaction t-PA with HUVEC reported by Beebe," Barnathan et al," and Aerts et aI.l3 Indeed, a direct comparison of t-PA binding to monocytes and monocytoid cells with HUVEC in suspension yielded very similar binding parameters. The affinity of t-PA for HUVEC in suspension is somewhat lower than reported by others for adherent HUVEC. In a direct comparison, adherent HUVEC bound t-PA with a kd = 20 f 10 nmol/L and 40 f 20 x lo4 binding sites per cell, whereas the HUVEC in suspension bound t-PA with a kd = 730 2 200 nmol/L and 1.1 f 1.0 x lo6 sites per cell. Technical differences in the analyses of adherent and nonadherent cells or differences in the character of t-PA receptors available on the luminal or abluminal cell surface could account for these observed differences in the binding parameters. Lysine and lysine analogues inhibited the binding of t-PA to the HUVEC as has been reported by These compounds also inhibited t-PA binding to monocytes and the two monocytoid cells. Indeed, the lysine analogues inhibited t-PA binding to these cells with similar IC,, values, suggesting that HUVEC and monocytoid cells share a similar recognition specificity for t-PA. Partial inhibition of t-PA binding to HUVEC by u-PA has been and could be attributable to competition of u-PA and t-PA for PAI-1 in the matrix or on the surface of the cells. With HUVEC in suspension and the monocytoid cells, u-PA was able to affect complete inhibition of t-PA binding. It is noteworthy that this inhibition was observed: (1) under conditions where t-PA binding was mediated by low-affinity rather than high-affinity (potentially PAI-1) sites; (2) in the absence of a matrix; and (3) with both active and inactive t-PA and with HMW-u-PA. Thus, the inhibition of t-PA binding by u-PA to monocytoid cells and HUVEC in suspension is unlikely to arise from competition for PAI-1. This competition was structurally specific as LMW-u-PA, factor XII, prothrombin, and protein C failed to compete. The growth factor domain of u-PA is responsible for the binding of this molecule to the cell surface with a high affinity (0.1 to 1 nmol/L), but much higher concentrations of HMW-u-PA were required to inhibit t-PA binding. Accordingly, an interaction of u-PA with t-PA, as suggested by Beebe et al,53 or a lower affinity binding site for u-PA on the cells, a site shared with t-PA, must be considered.
A high-affinity interaction of t-PA with several types of cells has been d e~c r i b e d . "~' *~~~~'~ The high-affinity binding of t-PA to HUVEC has been attributed to its interaction with PAI-1, an inhibitor that may also be present on monoc y t e~.~~ Thus, we have further explored the possibility of a high-affinity interaction between t-PA and monocytoid cells. While initial Scatchard plots were compatible with a high-affinity site for t-PA, further analyses indicated that, when appropriately corrected for nonspecific binding, only a single class of t-PA binding sites could be discerned. Further studies also failed to provide evidence of a highaffinity site for t-PA on these cells. When 1z51-rt-PA was added to the cells at a low concentration to maximize selective occupancy of a putative high-affinity site, the absence of a high-affinity interaction was supported by the observations that: (1) no SDS-stable complexes were formed when t-PA was bound to the cells; (2) IC,, values were similar for lysine analogues or HMW-u-PA at the high and at lower ligand concentrations; (3) a similar reduction of t-PA binding to CPB-treated cells was observed at dispar- In preliminary studies, we have indeed found that nonlabeled plasminogen in the 1 to 10 pmol/L range produced extensive inhibition of '2sI-rt-PA binding to the monocytoid cell lines. While such data may indicate that plasminogen and t-PA may share binding sites on these cells, the results must be interpreted with caution. If the added plasminogen becomes activated, either by plasminogen activators intrinsic to the cells or by the residual activity of the rt-PA ligand, the plasmin formed may alter the ligand or the cell surface and reduce binding. Inclusion of protease inhibitors may not be effective in preventing such alteration because plasmin formed on the cell surface may not be readily inhibitable." To approach this issue in a definitive manner, we are currently examining the inhibitory activity of isolated domains of t-PA and plasminogen on the binding of inactivatable mutants of the parent molecules. It is noteworthy that Hajjar and Hame156 have provided preliminary data that t-PA and plasminogen bind to different sites on the same molecule on endothelial cells. As monocytes and monocytoid cells can modulate their expression of plasminogen receptors," if these molecules share binding sites these cells also may be able to upregulate their t-PA binding. Furthermore, as these cells can be stimulated to synthesize t-PA,28.2' autocrine saturation of binding sites may occur. It should also be noted that the "nonspecific" binding of t-PA at low ligand concentrations occurred despite the presence of a substantial excess of carrier protein in the binding assays. At physiologic concentrations of t-PA, this nonspecific interaction could constitute a significant mechanism for association of t-PA with cells. Beyond these speculations, the present study directly shows that monocytes and monocytoid cells possess t-PA receptors, endowing them with an alternative to the u-PA-dependent pathway to assemble proteolytic activity on their cell surface. The role of these receptors in physiologic and pathologic processes and the possible interactions among the various fibrinolytic receptors and their ligands open intriguing possibilities for the regulation of the fibrinolytic system by these cells.
